BioCentury
ARTICLE | Financial News

Xeltis raises EUR 27M in series B

December 4, 2014 2:58 AM UTC

Regenerative medicine play Xeltis AG (Zurich, Switzerland) raised EUR 27 million ($33.6 million) in a series B round led by new investors Life Sciences Partners and Kurma Partners. New investor VI Partners and undisclosed existing investors, including family offices and angels, also participated.

Xeltis is developing synthetic biodegradable heart valve and blood vessel matrices designed to stimulate natural tissue growth. ...